New Delhi, 13 March (IANS). A scientific team is researching a new type of antibodies, which activates cancer cells by activating the body’s immunity and slows down the growth of the tumor of the breast and ovary cancer that is not cured despite treatment.
An antibodies called IGG are usually used as immunotherapy in the treatment of cancer. It helps the body’s immune system fight cancer and is considered an alternative to chemotherapy and radiotherapy. However, in some patients this treatment is not effective, especially in breast and ovary cancer associated with HER2, and sometimes the body develops immunity to this treatment.
To overcome this problem, scientists at King’s College London researched a different type of antibody called IGE. This antibody activates the immune system in a different way from IgG.
IgE antibodies awakens the immune cells of the body that are usually not active and are present around the tumor. This leads to direct targeting cancer cells.
Researchers prepared and tested IGE antibodies instead of IGG antibodies. Researcher Dr. Heather Bax, King’s College London, said IGE activated the immune system against cancer cells affected by HER2 and slowed down the growth of tumors in mice.
This tumor was developed in mice that do not have the effect of traditional treatment. This indicates that this new technology can be beneficial for patients on whom existing treatment does not work.
On further studies, scientists found that IGE antibody could re -activate the immune system around the tumor. This increases the immune system’s ability to fight cancer. The research is published in the Journal for Immunotherapy of Cancer (JITC).
According to Dr. Heather Bax, “About 20% of the breast and ovary cancer contains a marker called HER2. We prepared an IGE antibody against HER2 and found that it can activate the immune system in a new way. This can effectively target HER2 cancer cells, especially in cases where the current treatment does not work.”
He further said that this new discovery can become a new treatment option for patients suffering from HER2 cancer.
-IANS
AS/
